Developing a successful transdermal patch is a major undertaking. It oftentimes requires several years and millions of dollars. Far too often, drug developers underestimate the complexity of formulating a compound for transdermal delivery. Overcoming these unique challenges is something Tapemark was made for given our staff, experience, equipment, and facilities.
Transdermal patch development begins with formulating a concept for consistent, controlled drug delivery. When executed well, the transdermal route allows for better bioavailability and fewer side effects while increasing patient compliance. Tapemark’s capabilities cover every step of the journey from early development to full scale commercial manufacturing.
Our transdermal drug delivery experience includes branded (NDA and 505(b)(2)), generic, and OTC pharmaceuticals. We partner with clients for early-stage drug development—like formulation and small scale, handmade prototyping—all the way through large-scale registration and commercialization. Beyond early-stage development, TM has numerous successes with tech transfer projects and site-change initiatives.
Our transdermal patch experience extends to just about every type of patch on the market, including active, passive, iontophoresis, matrix, reservoir, island, and sophisticated multi-material patches. Within these subtypes, we have worked across many therapeutic areas, including oncology, pain, and CNS.
Transdermal patch drug delivery can be divided into two main subtypes: passive and active systems. Passive transdermal patches most often incorporate a drug-in-matrix layer between the release liner and backing layers. They provide a consistent diffusion rate depending upon the characteristics of the skin.
Alternatively, active transdermal patches typically use a reservoir system to contain the drug within a membrane. The diffusion properties of the membrane control drug availability. You will typically see the reservoir system used for formulations of higher molecular weight, which are known to be more difficult to transfer transdermally.
As a leading expert in both passive and active transdermal patch drug delivery, we excel in everything from simple projects to the most complex patches on the market.
"Tapemark has proven itself as a leader in development and manufacturing of pharmaceutical thin films. The team at Tapemark has been an invaluable partner in their expertise provided to support our technology transfers. They continue to be committed to the success of each of our projects."
“We have partnered with Tapemark over the years for our transdermal patch projects. We have found Tapemark to be a great partner. Tapemark has become a one stop shop for transdermal product development and commercial manufacturing after expanding its capabilities.”
“The Tapemark team met every technical challenge and applied the extra resources necessary for us to achieve a successful launch of one of our strategic products."
"We have partnered with Tapemark for several business-critical new product launches. We have found Tapemark to be flexible and customer-focused and willing to accommodate our changing needs to their best ability. It has been a pleasure working with the Tapemark team."
"We have partnered with Tapemark for our transdermal patch since 2013. We have found Tapemark to be a highly experienced and professional team. The most important aspect is however the collaboration between our companies in building a solid foundation for our partnership, mutual respect, and success in business."
"We have been a supplier to Tapemark for over 7 years and in our experience, the people at Tapemark are a pleasure to work with. We have created a mutually beneficial business relationship by working through all aspects of the supply chain. Our mutual commitment to meet regularly helps us plan together and has been very beneficial to ensure that we meet all the requirements established by Tapemark. Working with a company like Tapemark is rewarding for us and we are honored to participate in your mission by playing a role to assist in the delivery of non-invasive products that aid in pain treatment."